TY - JOUR
T1 - Phosphorylated STAT5 represents a new possible prognostic marker in Hodgkin lymphoma
AU - Martini, Maurizio
AU - Hohaus, Stefan
AU - Petrucci, Giovanna
AU - Cenci, Tonia
AU - Pierconti, Francesco
AU - Massini, Giuseppina
AU - Teofili, Luciana
AU - Leone, Giuseppe
AU - Larocca, Luigi Maria
PY - 2008
Y1 - 2008
N2 - An important pathogenetic mechanism in Hodgkin lymphoma (HL) is the interaction between the neoplastic and reactive cells mediated by a complex network of cytokines with activation of cytokine signal transduction (STAT) pathways. We studied the prognostic impact of the phosphorylation status of STAT5 in HL. By using immunohistochemical analysis, we found phosphorylated STAT5 (pSTAT5) in 35 (38%) of 93 lymph node biopsy specimens of patients with HL. The detection of pSTAT5 in Hodgkin and Reed-Sternberg (HRS) cells in classical HL (cHL) was not associated with any clinical and biologic features evaluated, including Epstein-Barr virus status. The primary end point for analysis of clinical outcome was freedom from treatment failure (FFTF). At a median follow-up of 5 years, pSTAT5+ patients with cHL had a better FFTF than pSTAT5-patients (77% vs 56%; P = .03), which translated into a reduced risk for failure for pSTAT5+ patients with a hazard ratio of 0.2 (95% confidence interval, 0.06-0.73; P = .015). Our data suggest that the phosphorylation status of STAT5 of HRS cells in cHL could be a prognostic marker in HL.
AB - An important pathogenetic mechanism in Hodgkin lymphoma (HL) is the interaction between the neoplastic and reactive cells mediated by a complex network of cytokines with activation of cytokine signal transduction (STAT) pathways. We studied the prognostic impact of the phosphorylation status of STAT5 in HL. By using immunohistochemical analysis, we found phosphorylated STAT5 (pSTAT5) in 35 (38%) of 93 lymph node biopsy specimens of patients with HL. The detection of pSTAT5 in Hodgkin and Reed-Sternberg (HRS) cells in classical HL (cHL) was not associated with any clinical and biologic features evaluated, including Epstein-Barr virus status. The primary end point for analysis of clinical outcome was freedom from treatment failure (FFTF). At a median follow-up of 5 years, pSTAT5+ patients with cHL had a better FFTF than pSTAT5-patients (77% vs 56%; P = .03), which translated into a reduced risk for failure for pSTAT5+ patients with a hazard ratio of 0.2 (95% confidence interval, 0.06-0.73; P = .015). Our data suggest that the phosphorylation status of STAT5 of HRS cells in cHL could be a prognostic marker in HL.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Epstein-Barr Virus Infections
KW - Hodgkin Disease
KW - Immunohistochemistry
KW - Kaplan-Meier Estimate
KW - Prognosis
KW - Reed-Sternberg Cells
KW - STAT5 Transcription Factor
KW - Survival Analysis
KW - Treatment Outcome
KW - Tumor Markers, Biological
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Epstein-Barr Virus Infections
KW - Hodgkin Disease
KW - Immunohistochemistry
KW - Kaplan-Meier Estimate
KW - Prognosis
KW - Reed-Sternberg Cells
KW - STAT5 Transcription Factor
KW - Survival Analysis
KW - Treatment Outcome
KW - Tumor Markers, Biological
UR - http://hdl.handle.net/10807/11662
U2 - 10.1309/63H1A83HRTBQ07DB
DO - 10.1309/63H1A83HRTBQ07DB
M3 - Article
SN - 0002-9173
VL - 129
SP - 472
EP - 477
JO - American Journal of Clinical Pathology
JF - American Journal of Clinical Pathology
ER -